ライフサイエンスコーパス: indoleamine

1 aled them as being similar to the endogenous indoleamine.

2 lation of circulating prostaglandin E(2) and indoleamine 2, 3,-dioxygenase enzymatic activity, as wel

3 HS suppressed mRNA and protein expression of indoleamine 2, 3-dioxygenase (IDO) and its activity upon

4 Production of indoleamine 2, 3-dioxygenase (IDO) by macrophages has re

5 recently shown that expression of the enzyme indoleamine 2, 3-dioxygenase (IDO) during murine pregnan

6 Indoleamine 2, 3-dioxygenase (IDO) is an immunoregulator

7 y modulating the expression of PD-L1; Tim-3; indoleamine 2, 3-dioxygenase (IDO); and interleukin 10.

8 The enzyme indoleamine 2, 3-dioxygenase (IDO-1) initiates and regul

9 on (IFN)-gamma induces the expression of the indoleamine 2, 3-dioxygenase (INDO) gene in human cells,

10 ly produced by both cell populations, unlike indoleamine 2, 3-dioxygenase which was only produced fol

11 tryptophan via the IFN-gamma-induced enzyme indoleamine 2, 3-dioxygenase.

12 was not mediated via induction of the enzyme indoleamine 2, 3-dioxygenase.

13 , depletion of Gr1(+) cells or inhibition of indoleamine 2,3 dioxygenase (IDO) activity abrogates gra

14 Indoleamine 2,3 dioxygenase (IDO) activity during pregna

15 amino acid TRP, cells expressing the enzyme indoleamine 2,3 dioxygenase (IDO) can mediate potent loc

16 Indoleamine 2,3 dioxygenase (IDO) catabolizes the amino

17 Indoleamine 2,3 dioxygenase (IDO) has emerged as an impo

18 d expression of the immune regulatory enzyme indoleamine 2,3 dioxygenase (IDO) in local lymph nodes.

19 Indoleamine 2,3 dioxygenase (IDO) is a catabolic enzyme

20 xpression of the tryptophan-degrading enzyme indoleamine 2,3 dioxygenase (IDO) is selectively induced

21 ha(-/-) mice was likely because of a lack of indoleamine 2,3 dioxygenase (IDO), a critical regulator

22 local draining lymph nodes (dLNs) to express indoleamine 2,3 dioxygenase (IDO), which confers T cell

23 aneously, pDCs up-regulate the expression of indoleamine 2,3 dioxygenase (IDO), which is essential fo

24 The roles of anergy and the indoleamine 2,3 dioxygenase (IDO)-tryptophan pathway in

25 tivating immunoregulatory mechanisms such as indoleamine 2,3 dioxygenase (IDO).

26 ressive factors IL-4, IL-10, CD274/PD-L1 and indoleamine 2,3 dioxygenase (IDO).

27 endent on the tryptophan catabolizing enzyme indoleamine 2,3 dioxygenase 1 (IDO1) in splenic macropha

28 , the SE inhibited the enzymatic activity of indoleamine 2,3 dioxygenase, a key enzyme in immune tole

29 Indoleamine 2,3 dioxygenase-1 (IDO-1) is an enzyme in th

30 Indoleamine 2,3 dioxygenase-1 (IDO1) catabolizes tryptop

31 y are associated with elevated expression of indoleamine 2,3 dioxygenase-1 (IDO1).

32 duces depressive-like behavior by activating indoleamine 2,3 dioxygenase.

33 factor alpha (TNF-alpha) and upregulation of indoleamine 2,3-deoxygenase (IDO) but not of Toll-like r

34 ve immune functions, including production of indoleamine 2,3-deoxygenase.

35 physiological importance of human placental indoleamine 2,3-dioxygenase (EC 1.13.11.42), the first a

36 that inhibition of enzyme activity in human indoleamine 2,3-dioxygenase (hIDO) and a number of site-

37 Human indoleamine 2,3-dioxygenase (hIDO) is an intracellular h

38 Human indoleamine 2,3-dioxygenase (hIDO) is an intracellular h

39 han 2,3 dioxygenase (hTDO), and the other is indoleamine 2,3-dioxygenase (hIDO), both of which cataly

40 nt in heme-based dioxygenases, such as human indoleamine 2,3-dioxygenase (hIDO), was not recognized u

41 in humans: tryptophan dioxygenase (hTDO) and indoleamine 2,3-dioxygenase (hIDO).

42 teins, tryptophan 2,3-dioxygenase (hTDO) and indoleamine 2,3-dioxygenase (hIDO).

43 Pharmacological inhibition of indoleamine 2,3-dioxygenase (IDO) activity during murine

44 ther gamma interferon (IFN-gamma) can induce indoleamine 2,3-dioxygenase (IDO) activity in aortic smo

45 higher levels of gamma interferon-inducible indoleamine 2,3-dioxygenase (IDO) activity than endothel

46 ike receptor (TLR) 4 signaling, can regulate indoleamine 2,3-dioxygenase (IDO) activity, favoring TH2

47 (IgM), cytokine/granzyme concentrations, and indoleamine 2,3-dioxygenase (IDO) activity.

48 cells could be attributed to their increased indoleamine 2,3-dioxygenase (IDO) activity.

49 describe a subset of human APCs that express indoleamine 2,3-dioxygenase (IDO) and inhibit T cell pro

50 h a focus on the tryptophan catabolic enzyme indoleamine 2,3-dioxygenase (IDO) and its recently disco

51 inhibitory effect was primarily mediated by indoleamine 2,3-dioxygenase (IDO) and prostaglandin E2 (

52 omotes immune suppression through the enzyme indoleamine 2,3-dioxygenase (IDO) and subsequent product

53 tivated inflammatory macrophages can express indoleamine 2,3-dioxygenase (IDO) and thus actively depl

54 Indoleamine 2,3-dioxygenase (IDO) and tryptophan 2,3-dio

55 ortage of tryptophan caused by expression of indoleamine 2,3-dioxygenase (IDO) and tryptophan 2,3-dio

56 eprogramming was suppressed by tumor-induced indoleamine 2,3-dioxygenase (IDO) and vaccination failed

57 Small-molecule inhibitors of indoleamine 2,3-dioxygenase (IDO) are currently being tr

58 Indoleamine 2,3-dioxygenase (IDO) catalyzes the breakdow

59 Indoleamine 2,3-dioxygenase (IDO) catalyzes the initial,

60 Tryptophan 2,3-dioxygenase (TDO) and indoleamine 2,3-dioxygenase (IDO) constitute an importan

61 aneous efficacy of serum and urine biomarker indoleamine 2,3-dioxygenase (IDO) enzyme activity and pe

62 CR analysis revealed a 5-fold enhancement of indoleamine 2,3-dioxygenase (IDO) expression in the tumo

63 Additionally, indoleamine 2,3-dioxygenase (IDO) expression was only mo

64 Indoleamine 2,3-dioxygenase (IDO) has immunoregulatory r

65 vation of the tryptophan catabolizing enzyme indoleamine 2,3-dioxygenase (IDO) in cancer cells facili

66 ously shown that an immunomodulatory enzyme, indoleamine 2,3-dioxygenase (IDO) in dermal fibroblasts

67 rucial role for the immunosuppressive enzyme indoleamine 2,3-dioxygenase (IDO) in GVHD regulation.

68 tent to express the T-cell regulatory enzyme indoleamine 2,3-dioxygenase (IDO) in mice treated with T

69 upregulated both the immunoregulatory enzyme indoleamine 2,3-dioxygenase (IDO) in plasmacytoid DCs an

70 critical role for the immune escape mediator indoleamine 2,3-dioxygenase (IDO) in supporting inflamma

71 Elevation of the immunomodulatory enzyme indoleamine 2,3-dioxygenase (IDO) in tumor cells can fac

72 n 4 (CTLA-4) blockade and treatment with the indoleamine 2,3-dioxygenase (IDO) inhibitor 1-methyl-D-t

73 n a prodrug conjugate of PEG with NLG919, an indoleamine 2,3-dioxygenase (IDO) inhibitor currently us

74 nt and include chemotherapeutics, radiation, indoleamine 2,3-dioxygenase (IDO) inhibitors, inhibitors

75 Indoleamine 2,3-dioxygenase (IDO) is a heme-containing d

76 Indoleamine 2,3-dioxygenase (IDO) is a heme-containing e

77 The heme enzyme indoleamine 2,3-dioxygenase (IDO) is a key regulator of

78 Indoleamine 2,3-dioxygenase (IDO) is a negative regulato

79 The immunosuppressive protein indoleamine 2,3-dioxygenase (IDO) is a rate-limiting enz

80 Indoleamine 2,3-dioxygenase (IDO) is a unique cytosolic

81 Indoleamine 2,3-dioxygenase (IDO) is an immunosuppressiv

82 bolism of the amino acid tryptophan (Trp) by indoleamine 2,3-dioxygenase (IDO) is considered an impor

83 Indoleamine 2,3-dioxygenase (IDO) is emerging as an impo

84 The immunoregulatory enzyme indoleamine 2,3-dioxygenase (IDO) is expressed by a subs

85 The immunosuppressive enzyme indoleamine 2,3-dioxygenase (IDO) is expressed by APCs a

86 The tryptophan-catabolizing enzyme indoleamine 2,3-dioxygenase (IDO) is expressed in macrop

87 y, expression of the immunoregulatory enzyme indoleamine 2,3-dioxygenase (IDO) is induced following i

88 Indoleamine 2,3-dioxygenase (IDO) is one molecular mecha

89 Indoleamine 2,3-dioxygenase (IDO) is the enzyme that cat

90 Indoleamine 2,3-dioxygenase (IDO) is the first and rate-

91 Indoleamine 2,3-dioxygenase (IDO) is the first and rate-

92 Indoleamine 2,3-dioxygenase (IDO) is the rate-limiting e

93 Here, we examine the inhibitory role of indoleamine 2,3-dioxygenase (IDO) on the antitumor effic

94 well as interfering in the immunosuppressive indoleamine 2,3-dioxygenase (IDO) pathway.

95 Tryptophan 2,3-dioxygenase (TDO) and indoleamine 2,3-dioxygenase (IDO) play a central role in

96 The heme enzyme indoleamine 2,3-dioxygenase (IDO) plays an important imm

97 ors of the tryptophan (Trp) catabolic enzyme indoleamine 2,3-dioxygenase (IDO) represent a vanguard o

98 Dendritic cell-derived indoleamine 2,3-dioxygenase (IDO) suppresses naive T cel

99 s study, we investigated the relationship of indoleamine 2,3-dioxygenase (IDO) systemic activity on c

100 The heme enzyme indoleamine 2,3-dioxygenase (IDO) was found to catalyze

101 In vivo blockade of indoleamine 2,3-dioxygenase (IDO) was performed, and its

102 In contrast, we found that the induction of indoleamine 2,3-dioxygenase (IDO) was required for the a

103 the tolerogenic tryptophan-degrading enzyme indoleamine 2,3-dioxygenase (IDO) were analyzed using fl

104 ithelial infection by inducing expression of indoleamine 2,3-dioxygenase (IDO), a host enzyme with pr

105 sed antitumor response through inhibition of indoleamine 2,3-dioxygenase (IDO), a key tolerogenic enz

106 The expression of indoleamine 2,3-dioxygenase (IDO), a known immunosuppres

107 duct brassinin to be a moderate inhibitor of indoleamine 2,3-dioxygenase (IDO), a new cancer immunosu

108 Indoleamine 2,3-dioxygenase (IDO), a potent immunosuppre

109 Br-brassinin) are bioavailable inhibitors of indoleamine 2,3-dioxygenase (IDO), a pro-toleragenic enz

110 s to HDAC inhibitors increased expression of indoleamine 2,3-dioxygenase (IDO), a suppressor of DC fu

111 through pathogen-specific local induction of indoleamine 2,3-dioxygenase (IDO), a tryptophan cataboli

112 re treated with a pharmacologic inhibitor of indoleamine 2,3-dioxygenase (IDO), a tryptophan-cataboli

113 ad7-deficient DCs expressed higher levels of indoleamine 2,3-dioxygenase (IDO), an enzyme associated

114 at M. tuberculosis induced the expression of indoleamine 2,3-dioxygenase (IDO), an enzyme involved in

115 blot analysis, which indicated induction of indoleamine 2,3-dioxygenase (IDO), an enzyme that conver

116 One ISG candidate, indoleamine 2,3-dioxygenase (IDO), an IFN-gamma-induced

117 Similar to CTLA-4 and FoxP3, expression of indoleamine 2,3-dioxygenase (IDO), an immunosuppressive

118 Indoleamine 2,3-dioxygenase (IDO), an interferon gamma-i

119 sing T cells (CARTs) through the activity of indoleamine 2,3-dioxygenase (IDO), an intracellular enzy

120 l-molecule immunotherapy agent that inhibits indoleamine 2,3-dioxygenase (IDO), encapsulated in the n

121 yptophan catabolism, initiated by the enzyme indoleamine 2,3-dioxygenase (IDO), is a critical partici

122 Although the tryptophan-degrading enzyme, indoleamine 2,3-dioxygenase (IDO), is a pivotal mediator

123 ted reduced toxicity as reflected by induced indoleamine 2,3-dioxygenase (IDO), suggesting discreet a

124 induce an IFNgamma-driven induction of host indoleamine 2,3-dioxygenase (IDO), the first and rate-li

125 Indoleamine 2,3-dioxygenase (IDO), the first and rate-li

126 We studied the expression of indoleamine 2,3-dioxygenase (IDO), the first enzyme in t

127 n of innate immunity, induces high levels of indoleamine 2,3-dioxygenase (IDO), the rate-limiting enz

128 f expressing the tryptophan-degrading enzyme indoleamine 2,3-dioxygenase (IDO), which allows them to

129 Indoleamine 2,3-dioxygenase (IDO), which degrades trypto

130 C production of the immunosuppressive enzyme indoleamine 2,3-dioxygenase (IDO), which depletes local

131 ations of RV-PV dysfunction with circulating indoleamine 2,3-dioxygenase (IDO)-dependent tryptophan m

132 ptophan oxidation products produced from the indoleamine 2,3-dioxygenase (IDO)-mediated kynurenine pa

133 ession of the tryptophan catabolizing enzyme indoleamine 2,3-dioxygenase (IDO).

134 l expression of the immunosuppressive enzyme indoleamine 2,3-dioxygenase (Ido).

135 s) up-regulate the immune-inhibitory enzyme, indoleamine 2,3-dioxygenase (IDO).

136 s a key pharmacophore in novel inhibitors of indoleamine 2,3-dioxygenase (IDO).

137 family of homologous enzymes, which includes indoleamine 2,3-dioxygenase (IDO).

138 LNs can express the immunoregulatory enzyme indoleamine 2,3-dioxygenase (IDO).

139 his tolerance is the immunoregulatory enzyme indoleamine 2,3-dioxygenase (IDO).

140 essed immunosuppressive levels of the enzyme indoleamine 2,3-dioxygenase (IDO).

141 expression of tryptophan-metabolizing enzyme indoleamine 2,3-dioxygenase (IDO).

142 in RA patients partly via the production of indoleamine 2,3-dioxygenase (IDO).

143 te-limiting enzyme of tryptophan catabolism, indoleamine 2,3-dioxygenase (IDO).

144 use tryptophan-catabolizing enzymes such as indoleamine 2,3-dioxygenase (IDO-1) to induce an immunos

145 ession of the tryptophan-catabolizing enzyme indoleamine 2,3-dioxygenase (IDO1) in human epithelial c

146 Indoleamine 2,3-dioxygenase (IDO1) is a tryptophan (Trp)

147 Tryptophan catabolism mediated by indoleamine 2,3-dioxygenase (IDO1) is an important mecha

148 he anti-inflammatory and anti-bacterial gene indoleamine 2,3-dioxygenase (IDO1) is dependent on STAT1

149 Indoleamine 2,3-dioxygenase (INDO) is the rate-limiting

150 Human indoleamine 2,3-dioxygenase 1 (hIDO1) is an attractive c

151 Since the discovery of indoleamine 2,3-dioxygenase 1 (IDO1) as an attractive ta

152 ses of two antiretroviral ISGs indicate that indoleamine 2,3-dioxygenase 1 (IDO1) can inhibit retrovi

153 as driven by IFN-gamma-mediated induction of indoleamine 2,3-dioxygenase 1 (IDO1) enzyme activity wit

154 Indoleamine 2,3-dioxygenase 1 (IDO1) is a key regulatory

155 Indoleamine 2,3-dioxygenase 1 (IDO1) is a single chain o

156 Indoleamine 2,3-dioxygenase 1 (IDO1) is an important the

157 Here, we report that brain indoleamine 2,3-dioxygenase 1 (IDO1), a rate-limiting en

158 tion, a host tryptophan-catabolizing enzyme, indoleamine 2,3-dioxygenase 1 (IDO1), is induced specifi

159 Indoleamine 2,3-dioxygenase 1 (IDO1), promoting immune e

160 ystemic inflammation only in the presence of indoleamine 2,3-dioxygenase 1 (IDO1).

161 asmid against the immunosuppressive molecule indoleamine 2,3-dioxygenase 1 (shIDO).

162 hermore, treatment of NKp44(+) NK cells with indoleamine 2,3-dioxygenase 1 catabolites in vitro ablat

163 inflammatory mediators in the gut, including indoleamine 2,3-dioxygenase 1.

164 Increased indoleamine 2,3-dioxygenase activity and consequent indu

165 cts of gamma interferon (IFN-gamma)-mediated indoleamine 2,3-dioxygenase activity on C. pneumoniae pe

166 The indoleamine 2,3-dioxygenase activity was assessed by mas

167 lls express high levels of CD163, CD206, and indoleamine 2,3-dioxygenase and secrete immunosuppressiv

168 grafts and increased expression of mRNAs for indoleamine 2,3-dioxygenase and the subunits encoding in

169 is an O2-dependent process and catalyzed by indoleamine 2,3-dioxygenase and tryptophan 2,3-dioxygena

170 With TDO and Indoleamine 2,3-dioxygenase as evolutionarily conserved

171 Inhibition of placental indoleamine 2,3-dioxygenase by 1-methyl-tryptophan preve

172 Indoleamine 2,3-dioxygenase catalyzes the O(2)-dependent

173 IL-27-induced indoleamine 2,3-dioxygenase enzymatic activity leads to

174 but not sequence homology to the two-domain indoleamine 2,3-dioxygenase enzyme (IDO).

175 on an omega-3 fatty acid derivative inducing indoleamine 2,3-dioxygenase expression in DC.

176 In human epithelial cells, IFN-gamma induces indoleamine 2,3-dioxygenase expression that inhibits chl

177 feron-gamma, which increases villous explant indoleamine 2,3-dioxygenase expression, has no effect on

178 ve increased accumulation of CD11c cells and indoleamine 2,3-dioxygenase expression.

179 ally sensitive to immunopharmacotherapy with indoleamine 2,3-dioxygenase inhibitors.

180 Abnormal tryptophan metabolism catalyzed by indoleamine 2,3-dioxygenase may play a prominent role in

181 rs such as TGF-beta, CTLA-4, PD-1, ICOS, and indoleamine 2,3-dioxygenase play an important role in im

182 Indoleamine 2,3-dioxygenase plays a key role in local tr

183 FN-gamma synthesis by donor T cells inducing indoleamine 2,3-dioxygenase synthesis by donor pDCs limi

184 ending on IFNgamma signaling and mediated by indoleamine 2,3-dioxygenase to a constitutive mechanism

185 leged media, which related to A20 preventing indoleamine 2,3-dioxygenase upregulation in SMC.

186 Indoleamine 2,3-dioxygenase was expressed on background

187 explants was markedly reduced when placental indoleamine 2,3-dioxygenase was stimulated with interfer

188 a number of suppressive enzymes, among which indoleamine 2,3-dioxygenase was sufficient to inhibit an

189 ic cell accumulation, expression of IL-2 and indoleamine 2,3-dioxygenase were evident in TLR4 compare

190 n (which is a known competitive inhibitor of indoleamine 2,3-dioxygenase) is a competitive inhibitor

191 ence of interferon-gamma (known to stimulate indoleamine 2,3-dioxygenase) tryptophan but not threonin

192 also inhibited PIV3, including IFITM1, IDO (indoleamine 2,3-dioxygenase), PKR (protein kinase, RNA a

193 r- beta 1+ cells, interleukin-10+ cells, and indoleamine 2,3-dioxygenase+CD3+ cells.

194 n-gamma-induced degradation of tryptophan by indoleamine 2,3-dioxygenase, activates the previously or

195 e, is similar to that of the large domain of indoleamine 2,3-dioxygenase, an enzyme that catalyzes th

196 g induction was mediated by DC expression of indoleamine 2,3-dioxygenase, and was confirmed in IDO-KO

197 Potential roles for indoleamine 2,3-dioxygenase, costimulatory molecules, an

198 We measured indoleamine 2,3-dioxygenase, interleukin-6, and transfor

199 ed during tryptophan metabolism initiated by indoleamine 2,3-dioxygenase, is known to induce T cell d

200 ane vesicles as part of a study on placental indoleamine 2,3-dioxygenase, the L-tryptophan-catabolisi

201 ophan limitation mediated by the host enzyme indoleamine 2,3-dioxygenase, which converts l-tryptophan

202 and primarily dependent on pDC expression of indoleamine 2,3-dioxygenase, which was induced through t

203 munodeficiency virus (HIV) infection-induced indoleamine 2,3-dioxygenase-1 (IDO) expression in activa

204 Small-molecule inhibitors of indoleamine 2,3-dioxygenase-1 (IDO1) are emerging at the

205 Indoleamine 2,3-dioxygenase-1 (IDO1; IDO) mediates oxida

206 ols, whereas level of messenger RNA encoding indoleamine 2,3-dioxygenase-1 was significantly increase

207 sistent with a common reaction mechanism for indoleamine 2,3-dioxygenase-catalyzed oxidation of trypt

208 ance of L-tryptophan transport for placental indoleamine 2,3-dioxygenase-mediated degradation of L-tr

209 nts both BCH and 1-methyl-tryptophan inhibit indoleamine 2,3-dioxygenase-mediated L-tryptophan degrad

210 e trophoblast to be a rate-limiting step for indoleamine 2,3-dioxygenase-mediated L-tryptophan degrad

211 his mechanism is dependent both on placental indoleamine 2,3-dioxygenase-mediated tryptophan degradat

212 cyte division was specifically suppressed by indoleamine 2,3-dioxygenase-mediated tryptophan depletio

213 the presence of H(2)O(2)/ONOO(-) deactivated indoleamine 2,3-dioxygenase.

214 of 2',5'-oligoadenylate synthetase, Mx1, and indoleamine 2,3-dioxygenase.

215 cells through the induction and activity of indoleamine 2,3-dioxygenase.

216 t in vitro (though not in vivo) inhibitor of indoleamine 2,3-dioxygenase.

217 a induces expression of p47 GTPases, but not indoleamine 2,3-dioxygenase.

218 hyl-tryptophan which is also an inhibitor of indoleamine 2,3-dioxygenase.

219 eam target, the tryptophan-catalyzing enzyme indoleamine 2,3-dioxygenase.

220 eries of substituted tryptophan analogues by indoleamine 2,3-dioxygenase.

221 were evaluated for their ability to inhibit indoleamine 2,3-dioxygenase.

222 of various tumor-promoting genes, including indoleamine 2,3-dioxygenase; and attenuation of these ch

223 uman (hIDO) and Shewanella oneidensis (sIDO) indoleamine 2,3-dioxygenases, Xanthomonas campestris (Xc

224 oring of tryptophan (trp) metabolism through indoleamine 2.3-dioxygenase (IDO) has been previously pr

225 levels of immune-inhibitory IL-10, IL12p40, indoleamine-2,3-dioxidase, and TIMP-1 (tissue inhibitor

226 proved SB transposon encoding the human gene indoleamine-2,3-dioxygenase (hIDO), an enzyme that posse

227 uced inducible nitric oxide synthase (iNOS), indoleamine-2,3-dioxygenase (IDO) and heme oxygenase (HO

228 Indoleamine-2,3-dioxygenase (IDO) and tryptophanyl-tRNA-

229 Expression of indoleamine-2,3-dioxygenase (IDO) by vascular endotheliu

230 The enzyme indoleamine-2,3-dioxygenase (IDO) catalyses degradation

231 t levo-1-methyl tryptophan (L-1MT) can block indoleamine-2,3-dioxygenase (IDO) expressed by human den

232 the tumor tissue by the rate-limiting enzyme indoleamine-2,3-dioxygenase (IDO) expressed in tumor cel

233 yptophan pools by gamma interferon-inducible indoleamine-2,3-dioxygenase (IDO) is believed to be the

234 ryptophan and kynurenine, metabolites of the indoleamine-2,3-dioxygenase (IDO) pathway.

235 roids augment MSC expression and activity of indoleamine-2,3-dioxygenase (IDO), a primary mediator of

236 Expression of indoleamine-2,3-dioxygenase (IDO), an immunosuppressive

237 m the induction of type I IFN-alpha/beta and indoleamine-2,3-dioxygenase (IDO)-mediated immunosuppres

238 ting environment via induction of the enzyme indoleamine-2,3-dioxygenase (IDO).

239 ibitor of the tryptophan catabolizing enzyme indoleamine-2,3-dioxygenase (IDO).

240 ential target as the immunoregulatory enzyme indoleamine-2,3-dioxygenase (IDO).

241 al burdens than control mice, underexpressed indoleamine-2,3-dioxygenase (Ido1) in lung endothelium a

242 in the promoter region of the gene encoding indoleamine-2,3-dioxygenase (IDO1) was found to be assoc

243 cells, possibly via stimulation of host cell indoleamine-2,3-dioxygenase activity, in a dose-dependen

244 ot reverse tolerance, but treatment with the indoleamine-2,3-dioxygenase antagonist 1-methyltryptopha

245 expression of tolerogenic mediators, such as indoleamine-2,3-dioxygenase, arginase, and TGF-beta, and

246 tor-kappaB, as well as the metabolic enzyme, indoleamine-2,3-dioxygenase, which breaks down tryptopha

247 xpression of the tryptophan-degrading enzyme indoleamine-2,3-dioxygenase.

248 ited T-cell reactivity through regulation of indoleamine-2,3-dioxygenase.

249 ulatory molecules including IL-10, CD25, and indoleamine-2,3-dioxygenase.

250 results demonstrate a role for induction of indoleamine-2,3dioxygenase in accelerating the local for

251 tation of the 5-HT2C receptor did not affect indoleamine affinity.

252 This study evaluates a series of indoleamine analogs as alternate substrates of AANAT.

253 nicotinamide adenine dinucleotide, retinol, indoleamines, and collagen provides crucial information

254 oxyl radicals exceeded that of melatonin, an indoleamine considered to be the most potent naturally o

255 enase involved in the degradation of several indoleamine derivatives and has been indicated as an imm

256 Gamma interferon (IFN-gamma)-induced indoleamine dioxygenase (IDO), which inhibits chlamydial

257 ssive molecules such as TGF-beta, IL-10, and indoleamine dioxygenase (IDO).

258 ve focused on three enzymes in this pathway: indoleamine dioxygenase (IDO1), kynurenine monooxygenase

259 was microbistatic but was independent of 2,3-indoleamine dioxygenase activity.

260 are involved in the synergistic induction of indoleamine dioxygenase in epithelial cells.

261 rect interaction between this side chain and indoleamines for the 5-HT2A receptor but not for the 5-H

262 Indoleamines, like melatonin and serotonin, are implicat

263 The role of the indoleamine melatonin in seasonal adaptations in birds h

264 actor in the production of catecholamine and indoleamine neurotransmitters and is also essential for

265 mediated T-cell proliferation, primarily via indoleamine oxidase (IDO).

266 methyl-D-tryptophan, a specific inhibitor of indoleamine-pyrrole 2,3-dioxygenase (IDO), but not by NS

267 xidase subunits (p47(phox) or gp91(phox)) or indoleamine-pyrrole 2,3-dioxygenase 1 with or without an

268 mice deficient for p47(phox), gp91(phox), or indoleamine-pyrrole 2,3-dioxygenase 1, suggesting that A

269 , AngII markedly increased the expression of indoleamine-pyrrole 2,3-dioxygenase in parallel with inc

270 se systems, sometimes in comparison with the indoleamine serotonin (5-HT), on performance on a variet

271 amines (norepinephrine and dopamine) and the indoleamine serotonin (5-HT).

272 The indoleamines studied were affected differently by mutati

273 ween plasma levels of BDNF and serotonin, an indoleamine that is specifically released from activated

274 -HT2A receptor decreased the affinity of all indoleamines, whereas the interchange mutation of the 5-